US 12,459,975 B2
Modified T cells and methods of their use
Marcela V. Maus, Lexington, MA (US); Matthew Frigault, Somerville, MA (US); and Mark Cobbold, Winchester, MA (US)
Assigned to The General Hospital Corporation, Boston, MA (US)
Appl. No. 16/476,628
Filed by The General Hospital Corporation, Boston, MA (US)
PCT Filed Jan. 10, 2018, PCT No. PCT/US2018/013177
§ 371(c)(1), (2) Date Jul. 9, 2019,
PCT Pub. No. WO2018/132479, PCT Pub. Date Jul. 19, 2018.
Claims priority of provisional application 62/529,130, filed on Jul. 6, 2017.
Claims priority of provisional application 62/519,960, filed on Jun. 15, 2017.
Claims priority of provisional application 62/444,590, filed on Jan. 10, 2017.
Claims priority of provisional application 62/444,616, filed on Jan. 10, 2017.
Prior Publication US 2021/0137978 A1, May 13, 2021
Int. Cl. C07K 14/005 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61K 40/46 (2025.01); A61K 40/50 (2025.01); C12N 5/0783 (2010.01)
CPC C07K 14/005 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4211 (2025.01); A61K 40/46 (2025.01); C12N 5/0636 (2013.01); A61K 40/50 (2025.01); C12N 2510/00 (2013.01); C12N 2710/16122 (2013.01)] 17 Claims
OG exemplary drawing
 
1. An isolated T lymphocyte modified to have reduced or eliminated expression of the T Cell Receptor (TCR), due to reduced or eliminated expression of a CD3ζ, T Cell Receptor Alpha Chain (TRAC), or T Cell Receptor Beta Chain (TRBC) gene relative to a T lymphocyte without modification, wherein the isolated T lymphocyte expresses a protein comprising US6, UL40 viral protein and signal protein peptide, and UL18.